Track KZR and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Kezar Life Sciences Inc
4000 Shoreline Court, South San Francisco, CA, United States, 94080
IPO
2018
Employees
9
Industry
Biotechnology
Sector
Healthcare
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20252-2
0
Analyst Ratings
3 analysts covering
Hold100%recommend hold
Buy
0
Hold
3
Sell
0